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STUDY PROTOCOL Open Access
Peer support for the maintenance of
physical activity and health in cancer
survivors: the PEER trial - a study protocol
of a randomised controlled trial
Kirsten N. Adlard1*, David G. Jenkins1, Chloe E. Salisbury1, Kate A. Bolam2, Sjaan R. Gomersall3,
Joanne F. Aitken4,6,7,8, Suzanne K. Chambers9,7,5,6, Jeff C. Dunn4,6,7,10, Kerry S. Courneya11 and Tina L. Skinner1
Abstract
Background: Despite an overwhelming body of evidence showing the benefits of physical activity (PA) and
exercise for cancer survivors, few survivors meet the exercise oncology guidelines. Moreover, initiating, let alone
maintaining exercise programs with cancer survivors continues to have limited success. The aim of this trial is to
evaluate the influence of peer support on moderate-to-vigorous PA (MVPA) and various markers of health 12
months following a brief supervised exercise intervention in cancer survivors.
Methods: Men and women previously diagnosed with histologically-confirmed breast, colorectal or prostate cancer
(n = 226), who are >1-month post-treatment, will be invited to participate in this trial. Once enrolled, participants
will complete 4 weeks (12 sessions) of supervised high intensity interval training (HIIT). On completion of the
supervised phase, both groups will be provided with written recommendations and verbally encouraged to achieve
three HIIT sessions per week, or equivalent exercise that meets the exercise oncology guidelines. Participants will be
randomly assigned to receive 12 months of peer support, or no peer support (control). Primary and secondary
outcomes will be assessed at baseline, after the 4-week supervised HIIT phase and at 3-, 6- and 12-months. Primary
outcomes will include accelerometry-derived MVPA and prescribed HIIT session adherence; whilst secondary
outcomes will include cardiorespiratory fitness ( _VO2peak), body composition, quality of life and select cytokines,
myokines and inflammatory markers. Random effects mixed modelling will be used to compare mean changes in
outcomes between groups at each time point. A group x time interaction will be used to formally test for
differences between groups (alpha =0.05); utilising intention-to-treat analyses.
Discussion: If successful, peer support may be proposed, adopted and implemented as a strategy to encourage
cancer survivors to maintain exercise beyond the duration of a short-term, supervised intervention. A peer support-
exercise model has the long-term potential to reduce comorbidities, improve physical and mental wellbeing, and
significantly reduce the burden of disease in cancer survivors.
Ethics: Human Research Ethics Committee of Bellberry Ltd. (#2015–12-840).
Trial registration: Australian New Zealand Clinical Trial Registry 12618001855213. Retrospectively registered 14
November 2018.
Trial registration includes all components of the WHO Trial Registration Data Set, as recommended by the ICMJE.
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Strengths and limitations of this trial
 This is the first randomised controlled trial to
investigate the effectiveness of peer support for
maintaining physical activity following a brief
supervised training intervention in cancer survivors.
 This trial will monitor changes in physical activity,
physical fitness, body composition, blood markers of
health, and indicators of quality of life for 12-months.
 If peer support is found to improve maintenance of
exercise for 12 months following a brief supervised
training intervention, it will emerge as an effective
means to improve the health and wellbeing of
people living with and beyond cancer.
 The applications of this trial will be limited to
people living with and beyond breast, colon and/or
prostate cancer.
Background
Cancer incidence is rapidly increasing with an estimated
18.1 million new cases and 9.6 million cancer deaths
worldwide in 2018 [1]. Whilst two thirds of all people di-
agnosed with cancer survive at least 5 years, many live
with reduced functional capacity, poor health-related
quality of life and high levels of fatigue [2, 3]. Clinically
significant cancer treatment-related adverse effects can
last for up to 10 years post-diagnosis; the enduring na-
ture of such effects highlights the need for long-term
management strategies to improve outcomes following
diagnosis and treatment for people with cancer [4, 5].
Higher levels of physical activity (PA) is associated with a
reduced risk of cancer recurrence [6], with an estimated 30–
40% risk reduction for both breast and colorectal cancer sur-
vivors [7, 8]. Emerging and accumulating evidence also
shows that PA may reduce the risk of prostate cancer recur-
rence [9]. Moreover, exercise interventions for cancer pa-
tients and survivors has also been shown to reduce cancer-
related fatigue [10], and improve psychological wellbeing
and quality of life [11], physical function [12], body weight
and composition [13], muscle strength and endurance [12],
immune function [14], and cardiorespiratory fitness [15].
A growing body of research shows that relatively high
intensity exercise can elicit rapid and significant improve-
ments in various markers of health across a range of dif-
ferent clinical populations [16–18]. Devin et al. (2016)
recently showed that 4 weeks of high intensity interval
training (HIIT) significantly increased cardiorespiratory
fitness ( _VO2peak , + 3.5 mL.kg
− 1.min− 1; p < 0.001) and led
to significant decreases in fat mass (− 0.74 kg; p < 0.002)
and increases in lean mass (+ 0.72 kg; p < 0.001) in colo-
rectal cancer survivors [19]. These results are clinically
meaningful when placed in the context of the Cooper
Centre Longitudinal Study results which estimated that an
increase in _VO2peak of 3.5 mL.kg
− 1.min− 1 was associated
with a 10% (hazard ratio, 0.90 95% confidence interval
[CI] [0.84–0.97]) decrease in cancer-specific mortality risk
[20]. Importantly, three HIIT sessions per week, each
comprising only 16min of high intensity exercise inter-
spersed with active recovery, allowed participants to meet
the ‘cardiovascular’ component of the current exercise on-
cology guidelines (150min per week of moderate or 75
min per week of vigorous aerobic exercise or an equiva-
lent combination) [21, 22]. In addition to HIIT being a
time-efficient, highly effective means of rapidly improving
health, Kampshoff et al. [23] have recently reported that
high intensity exercise, when compared to low-to-
moderate intensity exercise, results in greater improve-
ments in quality of life. When these findings are consid-
ered with those of Martin et al. [24], who found that
higher intensity exercise helps cancer survivors maintain
their motivation to exercise, the available, emerging re-
search indicates that HIIT holds potential for addressing
the long-term health of cancer survivors.
Despite the strong body of evidence showing the bene-
fits of PA and exercise for cancer survivors, research sug-
gests that very few cancer survivors meet the exercise
oncology guidelines [25–27]. Indeed, some studies have
shown that cancer survivors are less active than those who
have not had cancer [28]. For example, Galvao et al. [26]
reported only 12% of prostate cancer survivors meet the
current exercise oncology guidelines [21]. In addition,
Gomersall et al. [29] found that less than 25% of partici-
pants who start a physical activity program remain active
after 6 months [30]. Similarly, Courneya et al. [31] found
that without support, only 36% of patients with lymphoma
met exercise oncology guidelines 6months following an
intervention. These results substantiate the colloquially-
known ‘drop-off ’ in PA participation following the com-
pletion of PA interventions and may explain the typically
poor maintenance of health outcomes at longer-term
follow-up assessments post-intervention.
Maintaining exercise adherence and its subsequent health
benefits following supervised exercise interventions is
therefore an area of particular need in exercise oncology [2,
32]. To date, variations of support for improving and main-
taining the activity levels of cancer survivors have included
phone, text reminders and printed materials [33]. Although
these methods of behavioural support have shown efficacy
in cancer populations in the short to mid-term [34, 35],
they also have some inherent limitations, with the most
prominent being a lack of face-to-face interaction.
Peer support, which is underpinned by components of
social cognitive theory [36] and the theory of planned
behaviour [37], uses trained individuals who have shared
experiences and who provide knowledge, emotional, so-
cial and/or practical help to support others. Though peer
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support has been used to maintain physical activity
levels in patients recovering from cardiac surgery [38],
its effectiveness as a means of promoting and/or main-
taining physical activity in cancer survivors following a
brief supervised intervention warrants further investiga-
tion [39]. To date, interventions have seen promising in-
creases in PA among peer-supported cancer survivors
compared to contact controls [40, 41]. However, these
trials were conducted solely with female breast cancer
survivors. Thus, the generalizability of the findings to
survivors of other cancers and male cancer survivors re-
mains unknown. In addition, these interventions were
solely telephone-based despite interactive mediums of
intervention delivery (e.g. face-to-face delivery) being
particularly important for people in the early stages of
behaviour change [42]. Furthermore, these interventions
were relatively short, with support lasting only 12 weeks.
Therefore, the durability of these findings remains
unknown.
The primary aim of this trial is to evaluate the influ-
ence of peer support compared to no peer support on
MVPA 12months following a brief supervised exercise
intervention in cancer survivors. Secondarily, this trial
aims to determine the influence of peer support on vari-
ous exercise-related markers of health (cardiorespiratory
fitness, body composition, strength, quality of life, blood
biomarkers, overall physical activity and sedentary be-
haviour) 12 months following a brief supervised exercise
intervention in cancer survivors compared to those
without peer support. It is hypothesised that peer sup-
port will result in higher levels of MVPA and markers of
health 12 months follow a brief supervised exercise
intervention compared to those without peer support.
Methods
Study design
This two-arm randomised controlled trial will involve
men or women with a previous diagnosis of breast, colo-
rectal or prostate cancer. All participants and peer sup-
porters will first complete 4 weeks (12 sessions) of HIIT
supervised by Accredited Exercise Physiologists (AEP) at
the School of Human Movement and Nutrition Sciences,
The University of Queensland, Brisbane, Australia (‘su-
pervised phase’). On completion of the supervised phase,
participants will be stratified by gender and age before
being randomly assigned (1:1) to either a peer support
group or a non-peer support group. All will be provided
with written recommendations to maintain three HIIT
sessions per week, or an alternative equivalent that
meets the exercise oncology guidelines (i.e. 150 min per
week of moderate or 75 min per week of vigorous aer-
obic exercise or an equivalent combination), for 12
months [21, 22]. Those assigned to the peer support
group will have access to a peer who will provide sup-
port to meet the HIIT and/or exercise guidelines.
All participants will complete a series of assessments
(see Table 1) at baseline, at the end of the supervised
phase, and at 3-, 6- and 12-months following the super-
vised phase (see Fig. 1).
Participants
Men and women previously diagnosed with histologically-
confirmed breast, colorectal or prostate cancer (n = 226)
will be invited to participate.
Inclusion criteria
i. ≥ 18 years old;
ii. ≥ 1-month post-treatment for cancer and not an-
ticipating undergoing further treatment during the
study period; and
iii. Able to travel to the exercise testing and training
premises.
Exclusion criteria
i. Currently performing any regular HIIT sessions (> 4
sessions in the previous month);
ii. The presence of musculoskeletal, neurological,
respiratory, metabolic or cardiovascular conditions
that may prevent safe completion of the exercise
demands of the study; and
iii. Participant is pregnant or anticipates becoming
pregnant during the study period.
Participants will be required to obtain their doctor’s
approval and will be individually screened using a med-
ical history form and interview to confirm eligibility.
Discontinuation criteria
Individual participants will be discontinued from the
trial, in agreement with the participant’s doctor where
appropriate, if:
i. The participant is diagnosed with recurrence of
cancer and needs to recommence active cancer
treatment;
ii. It is deemed unsafe for the participant to continue
exercising without specialist exercise professional
supervision during the unsupervised phase of the
trial;
iii. The participant has any major surgery or health
condition arise within the study period that will
significantly affect their ability to participate in
exercise for a duration > 1 month;
iv. The participant becomes pregnant; or
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Participants will be recruited from the University of
Queensland, by way of media releases, presentations, ad-
vertisements in newsletters, newspapers, social media
and noticeboards. Participants will also be recruited via
the Cancer Council Queensland (CCQ) support group
network, CCQ 131120 telephone support service, CCQ
Registries and the Queensland Health Cancer Registry.
Potential participants, after meeting the eligibility cri-
teria and being advised of the study requirements by the
principal investigator, will receive the Participant Infor-
mation Sheet, Participant Consent Form, Medical
Table 1 Schedule of data collection
Assessment or Outcome Study Period
Time Point: Pre-FM FM Pre-SP Post-SP 3 M 6 M 12 M
Screening
Participant eligibility ✓
Adult Pre-Exercise Screening System ✓
Informed consent ✓
Doctor’s consent ✓
Medical history and current status ✓ ✓ ✓ ✓ ✓ ✓ ✓
Demographics ✓
Concomitant research study participation ✓ ✓ ✓ ✓ ✓ ✓ ✓
Primary Outcomes
Moderate-to-vigorous physical activity (MVPA) ✓ ✓ ✓ ✓ ✓
Secondary Outcomes
Cardiorespiratory fitness ( _VO2peak) ✓ ✓ ✓ ✓ ✓ ✓
Body composition (DXA) ✓ ✓ ✓ ✓ ✓
Anthropometry (BMI) ✓ ✓ ✓ ✓ ✓
Strength (isometric grip strength) ✓ ✓ ✓ ✓ ✓
Blood biomarkers (IL-6, IL-8, Hepcidin, TNF-α, IGF-1, IGF-2, IGFBP-3 and CRP) ✓ ✓ ✓ ✓ ✓
Self-reported physical activity (Godin) ✓ ✓ ✓ ✓ ✓
Sedentary behaviour and light physical activity (accelerometry) ✓ ✓ ✓ ✓ ✓
Quality of life and wellbeing (EORTC QLQ C-30, SF-36 and FACT-G) ✓ ✓ ✓ ✓ ✓
Cancer-related fatigue (FACIT-F) ✓ ✓ ✓ ✓ ✓
Insomnia (ISI) ✓ ✓ ✓ ✓ ✓
Symptom distress (BSI) ✓ ✓ ✓ ✓ ✓
Depression and anxiety (DASS, PHQ-9 and GAD-7) ✓ ✓ ✓ ✓ ✓
Participant:peer supporter relationship (Therapeutic Alliance) ✓ ✓ ✓ ✓ ✓
Self-efficacy ✓ ✓ ✓ ✓ ✓
Barriers and enablers to PA ✓ ✓ ✓ ✓ ✓
Tertiary Outcomes
Semi-structured interviews ✓
Physical activity preferences ✓ ✓ ✓ ✓ ✓
Economic evaluation (AQoL-8D) ✓ ✓ ✓ ✓ ✓
Adverse and serious adverse events ✓ ✓ ✓ ✓ ✓ ✓
Key: Pre-FM pre-familiarisation, FM familiarisation, Pre-SP pre-supervised phase, Post-SP post-supervised phase, 3 M 3-months post-randomisation testing, 6 M 6-
months post-randomisation testing, 12 M 12-months post-randomisation testing, _VO2peak peak volume of oxygen consumption, DXA dual energy X-ray
absorptiometry, BMI body mass index, IL-6 interleukin 6, IL-8 interleukin 8, TNF-α tumour necrosis factor – alpha, IGF-1 insulin-like growth factor 1, IGF-2 insulin-like
growth factor 2, IGFBP-3 insulin-like growth factor-binding protein 3, CRP C-reactive protein, Godin Godin Leisure-Time Physical Activity Questionnaire, EORTC QLQ
C-30 European Organization for Research and Treatment of Cancer quality of life questionnaire for people with cancer, SF-36 Short form 36 health survey, FACT-G
Functional Assessment of Cancer Therapy: General, FACIT-F The Functional Assessment of Chronic Illness Therapy: Fatigue, ISI Insomnia Severity Index, BSI Brief
Symptom Inventory, DASS Depression Anxiety Stress Scale, PHQ-9 Patient Health Questionnaire-9, GAD-7 Generalised Anxiety Disorder 7-item scale, PA physical
activity, AQoL-8D Assessment of Quality of Life – 8 Dimensions Multi-Attribute Utility Instrument
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History Form and Medical Doctor Consent Form. Each
will then be contacted by telephone by the principal in-
vestigator to discuss any questions they may have re-
garding the trial. If they wish to continue they will be
required to obtain their Doctor’s written consent and
sign the Participant Consent Form, both of which will be
collected and securely stored by the primary
investigator.
Recruitment and training of peer supporters
Peer supporters, who will also be cancer survivors, will
be recruited through CCQ’s existing peer-support net-
work in addition to the aforementioned participant re-
cruitment pathways. Peer supporters will complete the
same consent and screening procedures as the study
participants. Each peer supporter will undergo CCQ’s
peer support training course, delivered over one or two
consecutive days (approximately 8 h per day). CCQ’s
course helps to equip volunteers with the skills required
to provide appropriate emotional support to those af-
fected by cancer, based on their shared experience with
cancer either as a patient; the premise of which origi-
nates from the Social Cognitive Theory [36]. CCQ’s peer
support training is also an opportunity for prospective
peer supporters to develop a better understanding of
their upcoming role, to ask questions, and to hear from
more established volunteers. Course outcomes aim to
educate peer supporters on how to support their partici-
pant to build motivation, improve confidence and facili-
tate self-efficacy within the exercising context.
The CCQ peer support training is primarily deliv-
ered face-to-face with an accompanying pre-reading
package outlining CCQ values, organisational struc-
ture, and introductory knowledge of cancer, treat-
ments, and CCQ support services. Information
delivered face-to-face utilizes digital presentations,
scenario group work, and personal reflections. More-
over, didactics and role play with investigator feed-
back will be used to enhance the peer supporters’
counselling skills. Peers will also receive training on
monitoring participant safety during exercise and
what to do should an adverse or serious adverse
event occur. An adverse event will be defined as ‘any
untoward medical occurrence in a participant subject
to the intervention’. A severe adverse event will be
defined as ‘any event requiring hospitalisation or
causing an inability to carry out usual activities’. Ad-
verse events will be assessed by monitoring and re-
cording during all exercise sessions by the supervising
Exercise Physiologist.
Peer supporters will perform the same supervised 4-
week HIIT phase as described for the participants to fa-
miliarise them with the demands of the prescribed exer-
cise protocol. The supervising AEP uses these sessions
to further educate and reiterate to the peer supporters
on the specifics of the exercise protocols and safety
measures.
Randomisation
Following completion of the 4-week supervised training
phase and the second testing session, participants will be
stratified by sex and age before being randomly assigned
(1:1 allocation ratio) to either a peer support group or a
non-peer support group. Randomisation will be per-
formed using a computerised random number generator
by a research officer independent to the study. Non-
systematic block sizes of four, six, or eight will be used
to ensure allocation concealment. Randomisation history
will be kept secure by the independent research officer
in an electronic password-protected file. The independ-
ent research officer will confidentially communicate the
allocation result to the trial’s primary investigator within
48 h after completing outcome testing following the sec-
ond testing session. All investigators will be blinded to
group allocation for baseline testing, the supervised
phase and for testing following the supervised phase,
with randomisation occurring after the completion of
testing following the supervised phase. The primary out-
come will be analysed by a researcher blinded to group
allocation. Unblinding will not be permissible under any
circumstances. A schematic representation of the study
protocol is shown in Fig. 1.
Fig. 1 Schematic timeline of the study. Key: *: following randomisation; HIIT: high intensity interval training
Adlard et al. BMC Cancer          (2019) 19:656 Page 5 of 15
4-week supervised high intensity interval training phase
Following familiarisation with the procedures, partici-
pants will complete 12 HIIT sessions over 4 weeks, su-
pervised by an AEP. Training sessions will be conducted
at the School of Human Movement and Nutrition Sci-
ences, The University of Queensland, and be performed
in small groups of less than five participants. Prior to ex-
ercising, participants’ heart rate and blood pressure will
be measured to indicate any contraindications to com-
mencing exercise as outlined by the American College of
Sports Medicine [43]. Each training session will follow
the procedure as previously described by Devin et al.
[19] (see Fig. 2).
12-month maintenance phase
Following completion of the 4-week supervised phase,
all participants will be encouraged to maintain three
HIIT sessions a week – a training commitment that will
have them meet the ‘cardiovascular’ component of the
American College of Sports Medicine’s exercise oncology
guidelines. All participants will be provided with 12-
months free access to exercise training facilities located
at multiple sites across South-East Queensland. Each ex-
ercise facility will be fitted with specific cycle ergometers
and heart rate monitors to enable participants to
complete HIIT sessions, and for the research staff to ac-
curately monitor all sessions over the 12-month main-
tenance phase.
Peer support intervention
Participants randomised to the peer support group will
be assigned a peer supporter. Assignment will be deter-
mined by training time availability and preference to en-
hance the ease of scheduling face-to-face exercise
sessions. The peer supporter will maintain weekly con-
tact (by phone, email and/or joining training sessions)
with their participant for the 12-month maintenance
phase. Contact frequency and type will be diarised by
the peer supporter following each occurrence. The peer
supporter’s goal will be to encourage their participant to
maintain physical activity levels throughout the 12-
month training period, equivalent to those achieved dur-
ing the supervised phase. Peer supporters will be en-
couraged to use the knowledge and strategies gained
from the CCQ peer support training sessions during dis-
cussions with their participants i.e. goal setting and plan-
ning, facilitating self-efficacy, improving confidence,
overcoming barriers and building motivation. Where
peer supporters have difficulty maintaining the recom-
mended weekly contact regime, they will be encouraged
to notify the research team to discuss and apply appro-
priate strategies moving forward. Participants will be re-
quired to diarise each exercise training session. Cycle
ergometers will record each exercise session and data
will be periodically retrieved by the researcher team. The
training diaries and cycle ergometer data, in conjunction
with the accelerometer data, will be used to assess main-
tenance to physical activity and the prescribed exercise
over the 12months.
Outcomes
Primary and secondary outcomes will be measured at
baseline, at the end of the 4-week supervised phase, and
at 3-, 6- and 12-months following the supervised phase.
See Table 1 for a visual representation of the data collec-
tion schedule.
Assessments will be performed in a consistent order
to allow for appropriate rest periods and to ensure that
successive outcomes are minimally influenced by accu-
mulative testing-fatigue. Participants will be advised to
take prescribed medications as normal throughout the
study period. Concomitant study participation will be
documented at each testing session and the primary in-
vestigator will determine whether any co-intervention
Fig. 2 Schematic representation of the HIIT protocol. Key: HRpeak: Peak heart rate, as determined by the most recent peak oxygen consumption ( _V
O2peak) test; min: minutes
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bias may influence the trial outcomes. Hospital admis-
sions and any alterations in medical status or medica-
tions will be recorded at each assessment for future
reference during analysis of results.
Testing standardisation measures
At each testing session, participants will be asked to: (i)
maintain a hydrated state in the 24 h prior to testing; (ii)
abstain from caffeine and alcohol intake for 12 h prior to
testing; and (iii) avoid any vigorous, high or unaccus-
tomed moderate intensity exercise or physical activity
for the preceding 48 h. Prior to the baseline testing ses-
sion, participants will be required to record a 3-day diet
diary, of which they will follow prior to all subsequent
testing sessions. Participant adherence to the testing
standardisation measures will be evaluated prior to the
commencement of each assessment. If testing standard-
isation measures are not met, the assessment will be
rescheduled for the following day and the leading re-




The primary outcome for this study will be MVPA at
12 months. MVPA can be accrued through perform-
ance of the prescribed HIIT sessions and/or by en-
gaging in any MVPA. Daily physical activity will be
assessed through the use of training diaries, retrieval
of HR and Wattbike ergometer data from each train-
ing session, as well as Actigraph GT3X+ accelerome-
try (Pensacola, Florida). Participants will be asked to
wear an accelerometer on an elastic waist belt aligned
with the right anterior axillary line for 7 days immedi-
ately preceding baseline, 3-, 6- and 12-month assess-
ments. Participants will be asked to complete a brief
log to record when they wear the monitor, including
wake and sleep times and if they removed the moni-
tor for > 10 min. They will be instructed to wear the
device at all times, excluding sleep, any water-based
activities (e.g. showering/swimming) and contact
sports. Accelerometers will be initialised with 30 s
epochs and a 30 Hz sampling frequency. A valid day
will be defined as a minimum wear-time of 10 waking
hours, with non-wear time defined as 60 min or more
of consecutive activity counts of zero. For activity
data to be included, participants must satisfy a mini-
mum wear-time criterion of at least four of the 7
days, with at least one of the days being a weekend
day [44, 45]. Minutes of MVPA will be calculated
using Actilife v6 (Pensacola, Florida) and the cut-
points described by Troiano et al. [44].
Secondary outcomes
Cardiorespiratory fitness ( _VO2peak)
Cardiorespiratory fitness represents a strong predictor of
decreased total cancer mortality risk, independent of
adiposity [46, 47]. _VO2peak and exercise duration during
the _VO2peak test will be used as measures of cardiorespi-
ratory capacity. The _VO2peak test will be conducted as
previously described by Devin et al. [48].
Body composition
High adipose tissue and reduced skeletal muscle has
been associated with poorer short-term recovery follow-
ing cancer treatment and poorer survival [49, 50]. Fur-
thermore, a decline in bone mineral density, particularly
trabecular density, has been correlated with increased
fracture risk and subsequent decreased quality of life
[51]. Regional and whole-body lean mass, fat mass and
bone mineral density will be measured using dual energy
x-ray absorptiometry (DXA, Hologic Discovery A, Wal-
tham, MA) as previously described by Devin et al. [19]
and Bolam et al. [52]. The coefficients of variation values
in our laboratory are < 1.1%.
Anthropometry
Obesity, particularly around the abdomen, has been dir-
ectly associated with risk of several types of cancer, in-
cluding cancer of the breast and colon. In addition, both
body mass index (BMI) and waist circumference have
been separately associated with a decrease in global
health status, functioning and symptoms of fatigue [53].
Therefore, prevention of weight gain is important for re-
ducing the risk of cancer recurrence [54–56].
Height and body mass will be measured using a stadi-
ometer (Seca, Birmingham, UK) and electronic scales (A
& D Mercury, Pty Ltd., Thebarton, Aus.), respectively,
from which BMI will be calculated. Waist and hip cir-
cumference will be measured using an anthropometric
steel tape measure (Lufkin W606M retractable steel
tape; Cooper Tools), from which a waist-to-hip ratio will
be determined. All anthropometrics will be measured ac-
cording to the International Society for the Advance-
ment of Kinathropometry (ISAK) procedures [57].
Measures will be recorded to the nearest 0.1 cm or 0.01
kg in duplicate, with mean values used in subsequent
analyses. If duplicate measures vary by ≥2%, a third
measure will be taken with the median value used in
subsequent analyses.
Isometric grip strength
Cancer treatment commonly results in reduced muscle
strength which leads to decreased functional capacity
and potential declines in quality of life and survival [58,
59]. Dominant and non-dominant handgrip strength will
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be assessed using a spring-loaded grip dynamometer
(TTM, Tokyo, Japan) to estimate physical performance
and muscular strength [60]. Participants will perform a
3-s maximal contraction with each hand maintaining a
90o elbow flexion and limit accessory movements [61].
Three trials will be performed on each side, alternating
between the dominant and non-dominant hand with the
best result used in subsequent analysis. A rest period of
at least 30 s will be provided between subsequent
attempts.
Blood biomarkers
Resting samples of venous blood (20 ml) will be drawn
by a qualified and experienced phlebotomist. Plasma and
serum samples will be separated according to standard
procedures and stored in a − 80 °C freezer for subse-
quent batch testing. Plasma samples will be analysed for
interleukin 6, interleukin 8, tumour necrosis factor –
alpha and C-reactive protein, which have been identified
as key mediators of neuro-immune interactions associ-
ated with post-treatment fatigue in cancer survivors [62,
63]. Additional analyses of insulin-like growth factor-1
(IGF-1), − 2 (IGF-2), and -binding protein-3 (IGFBP-3)
will be explored as plausible mechanisms underpinning
the inverse association between physical activity and
cancer progression [64]. Plasma cytokines will be
assessed using high-sensitivity ELISAs (R&D Systems,
Minneapolis, MN) following the manufacturer’s specifi-
cations. Quality control procedures for the laboratory
will be conducted in the manner reported by Aziz et al.
[65]. All samples for a given participant will be run in
parallel to minimise inter-assay variability.
Self-reported physical activity (Godin leisure-time physical
activity questionnaire)
Leisure-time PA is a primary domain of intervention
and research in public health [66]. Compared to other
forms of physical activity (e.g. occupational), leisure-time
PA may provide the greatest opportunity for enjoyment
and improvement in cardiorespiratory fitness and health
[67, 68]. The Godin Leisure-Time Physical Activity
Questionnaire is a frequently used measure of leisure-
time PA and will be completed at all testing time points
[69]. The questionnaire requires participants to recall
during a typical 7-day week the frequency and duration
of exercise completed at three separate intensities: mild,
moderate, and strenuous intensity. These values are used
to calculate a weekly leisure-time activity index based on
summing the frequency of sessions completed multiplied
by a weighting factor for each level of intensity. The
Godin questionnaire has been shown to have a modest
correlation compared with accelerometry-derived mea-
sures of physical activity (r = 0.45) but demonstrates high
test-retest reliability (r = 0.75) [70–72].
Sedentary behaviour and light physical activity
Sedentary behaviour (SB) is an independent risk factor
for cancer incidence and mortality [73]. Comparably,
moderate-to-vigorous intensity exercise generally de-
livers the greatest health benefits [74]. Exercise guide-
lines for people with cancer [22], however, acknowledge
that any PA, including light physical activity (LPA), is
better than none [73, 75]. Therefore, SB and LPA will be
assessed using Actigraph GT3X+ accelerometry (Pensa-
cola, Florida), following the methods described for
MVPA. Time spent in SB will be calculated using Acti-
life v6 (Pensacola, Florida) and the cutpoints described
by Matthews et al. [45] and time spent in LPA will be
determined as the time spent above the SB cutpoint (≤
100 counts per minute) and below the MVPA cut-point
(≥ 2020 counts per minute) [44, 45].
Cancer-specific quality of life (EORTC QLQ-C30)
The European Organization for Research and Treatment
of Cancer quality of life questionnaire for people with
cancer is designed to assess quality of life in cancer pa-
tients and holds good internal consistency and clinical
validity [76]. The EORTC QLQ-C30 [76–79] is a 30-
item cancer-specific instrument including nine multi-
item scales; five functional scales (physical, role, cogni-
tive, emotional, and social); three symptom scales (fa-
tigue, pain, and nausea and vomiting); and a global
health and quality-of-life scale. The EORTC QLQ-C30
questionnaire has been shown as reliable and valid for
use in cancer populations [78].
General health and wellbeing (SF-36)
The Medical Outcomes Study 36-item short-form 36
Health Survey (SF-36) will be used to assess general
health and wellbeing domains of physical and mental
health [80]. The SF-36 is scored through a set of eight
scales encompassing physical and mental health mea-
sures. This survey has been shown to be reliable and has
been validated for comparing general and specific popu-
lations, and estimating the relative burden of disease
[81].
Health-related quality of life (FACT-G)
Quality of life will be measured using the Functional As-
sessment of Cancer Therapy-General (FACT-G) self-
report questionnaire [82]. The FACT-G comprises four
subscales: Physical Well-Being (PWB), Social/Family
Well-Being (SWB), Emotional Well-Being (EWB), and
Functional Well-Being (FWB). The FACT-G has been
widely used in clinical trials, is relatively simple, and has
demonstrated sensitivity according to the performance
status and extent of disease [82, 83]. This questionnaire
has been extensively used in oncology clinical trials, due
to its ease of administration, brevity, reliability, validity,
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and responsiveness to clinical change [82]. The English
language version of the FACT-G will be self-
administered by participants.
Cancer-related fatigue (FACIT-F)
Fatigue will be assessed by the Functional Assessment of
Chronic Illness Therapy Fatigue Subscale Questionnaire
(FACIT-F) as described by Yellen et al. [84]. The FACIT-
F is a 13-item fatigue subscale utilising a five-point
Likert self-report scale ranging from 0 (not at all) to 4
(very much so). The total score varies from 0 (worst
condition) to 52 (best condition) and is calculated as a
sum of all items. The score is determined after re-
parameterization of items 7 (I have energy) and 8 (I am
able to do my usual activities) where 0 is worst condition
and 4 is best condition, which have an inverse relation-
ship to the other 11 subscale items. The FACIT-F ques-
tionnaire is reliable and has previously been validated
for predicting efficacy in treatment outcomes in
oncological-induced fatigue with high sensitivity (0.92)
and reasonable specificity (0.69) [85]. Furthermore, con-
vergent and discriminant validity testing has previously
demonstrated a significant positive relationship with
other measures of fatigue and a negative correlation with
vigour [86].
Insomnia (ISI)
The Insomnia Severity Index (ISI) is a seven-item meas-
ure of the nature, severity and impact of insomnia on a
Likert scale (0 = not at all, to 4 = very much) [87]. Ques-
tions relate to the subjective qualities of the respondents’
sleep, including satisfaction with sleep patterns, the de-
gree to which insomnia interferes with daily functioning,
and how the respondent feels their insomnia is notice-
able to others [88]. The ISI has shown internal validity
(r = 0.76) in insomnia diagnosis [87], and reliability of
α = 0.90 in breast and prostate cancer [89].
Psychological distress (BSI)
The Brief Symptom Inventory (BSI) [90] is a 53-item
self-report symptom inventory that assesses nine pat-
terns of clinically relevant psychological symptoms. It is
a brief version of the Symptom Checklist List 90-R
(SCL-90-R). Correlations between the BSI and SCL-R-90
are reported to range from 0.92 to 0.99 [90, 91]. Partici-
pants rate the extent to which they have been bothered
(0 =“not at all” to 4 = “extremely”) in the past week by
various symptoms [91]. The nine dimensions assessed
are: somatization, obsession-compulsion, interpersonal
sensitivity, depression, anxiety, hostility, phobic anxiety,
paranoid ideation and psychoticism. The BSI also in-
cludes three indices of global distress: Global Severity
Index, Positive Symptom Distress Index, and Positive
Symptom Total. The BSI has been used in a variety of
clinical and counselling settings as a mental health-
screening tool and as a method of measuring symptom
reduction during and after treatment. Research has pre-
viously found somatisation and anxiety to be related to
physical activity levels in colorectal cancer survivors
[92].
Depression, anxiety and stress scale (DASS)
The DASS questionnaire is a 42-item self-report instru-
ment design to measure the three related negative emo-
tional states of depression, anxiety, and stress [93].
Participants will be asked to plot their relative emotional
feelings on a 0–3 scale (i.e. 0 being ‘did not apply to me
at all’ and 3 being ‘applied to me very much, or most of
the time) over each emotional domain [93]. The DASS
has been clinically validated in measuring emotional
states of depression, anxiety and stress in clinical popu-
lations and has good reliability and moderate sensitivity
[94].
Depression and generalised anxiety (PHQ-9)
Depression is highly prevalent among people with can-
cer, with rates of depressive spectrum disorders as high
as 58% [95]. The Patient Health Questionnaire-9 (PHQ-
9) is a multipurpose instrument that will be used to as-
sess severity of depression [96]. The diagnostic validity
of the PHQ-9 was established in studies involving eight
primary care and seven obstetrical clinics. PHQ scores
≥10 had a sensitivity of 88% and a specificity of 88% for
major depression [96, 97]. PHQ-9 scores of 5, 10, 15,
and 20 represents mild, moderate, moderately severe
and severe depression [98].
Generalised anxiety disorder (GAD-7)
Approximately 20% of long-term cancer survivors report
anxiety symptoms [99]. The GAD-7 is a self-
administered patient questionnaire used as a screening
tool and severity measure for generalised anxiety dis-
order [100]. GAD-7 has seven items, which measure se-
verity of various signs of GAD according to reported
response categories with assigned points [100].
Participant:peer supporter relationship
The quality of the bond between the peer-supporters
and their participants will be assessed using an adapted
version of the Working Alliance Inventory (WAI) ques-
tionnaire [101]. The WAI is a 7-point Likert-type meas-
ure that assesses 12 alliance dimensions including
‘agreement on task’, ‘agreement of goals’ and ‘develop-
ment of bonds’, amongst others [102, 103]. The WAI has
demonstrated high construct validity and high internal
consistency estimates [103]. The WAI has been adapted
for terminology relevance regarding ‘HIIT’ and ‘peers’ in
this study. Furthermore, the 7-point Likert scale has
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been condensed to a 5-point Likert scale for consistency
and ease of interpretation with the other study
questionnaires.
Self-efficacy
To assess self-efficacy beliefs, participants will review the
exercise recommendations for this trial (3 x HIIT ses-
sions per week), and indicate the extent to which they
feel capable of successfully adhering to these recommen-
dations. Specifically, participants will be asked to what
extent they would rate the truth of the statement ‘I feel
capable of successfully completing 3 x HIIT sessions per
week for 4 weeks, 3 months, 6 months, 9 months, and
12 months’, respectively. Participants will be asked to
rate their responses on a 5-point Likert scale ranging
from ‘strongly disagree’ to ‘strongly agree’. This method
of assessing self-efficacy has been adapted from the Self-
Efficacy for Exercise (SEE) scale which was originally de-
scribed and validated in older adults by Resnick & Jen-
kins [104].
Barriers and enablers to exercise participation
Barriers and enablers to exercise participation will be
assessed via two open-ended written questions about
barriers and enablers to physical activity/exercise, as de-
scribed by Evenson et al. and Macniven et al. [105, 106].
The barrier question will ask: ‘What is the one main rea-
son that makes it harder for you to be more active?’.
The enabler question will ask: ‘What is the one main
reason that helps you to be more active?’. Two investiga-
tors will code responses and any discrepancies will be re-
solved by consensus. These items will be grouped into
meaningful categories considering the socioecological
framework, with intrapersonal, interpersonal, neighbor-
hood or environmental, and organizational or policy
categories.
Participants will also be asked to provide statements
based on the Behavioural Regulation in Exercise Ques-
tionnaire Version 2, as previously used by Martin et al.
and Markland et al. [24] [107]. Participants will be asked
to respond to matrix-based questions such as ‘I find it
difficult to exercise because of fatigue’ and ‘I am moti-
vated to perform exercise because it will improve my
physical health’. Participants will rate their agreement
with the statements on a 5-point Likert scale ranging
from ‘strongly disagree’ to ‘strongly agree’.
Tertiary outcomes
Semi-structured interviews
At the end of each individual’s involvement in the study,
participants and peer supporters will be invited to par-
take in a semi-structured interview (approximately 1 h)
in-person or via telephone regarding their views and ex-
periences throughout the trial. This will include study
completers, as well as those who withdraw or fail to
complete the study. Interview questions will focus on
the participant’s experiences as a cancer survivor, with
exercise and their participation in the trial. Peer sup-
porters and participants who were randomised to receive
peer support will be asked additional questions on their
experiences providing and receiving peer support, re-
spectively. Interviews will be audio-recorded and tran-
scribed verbatim before undergoing inductive thematic
analysis [108].
Physical activity preferences
The physical activity preference questionnaire will be
used to assess the physical activity context preferred by
participants throughout the duration of the trial due to
its potential role as a covariate [109]. The questionnaire
assesses physical activity preferences for 14 contexts of
format (e.g. vigorous), location (e.g. outdoors), and social
setting (e.g. done alone). Participants will be asked to
provide ratings that reflect their agreement with one of
two bi-polar statements at each end of the continuum
(e.g. ‘Strongly disagree’ – ‘Strongly agree’) [110].
Assessment of quality of life – 8 dimensions multi-attribute
utility instrument (AQoL-8D)
The AQoL-8D is a Multi-Attribute Utility (MAU) in-
strument which will be used to assess health state utility
at baseline, immediately following the supervised phase,
and at 3, 6 and 12 months [111]. The AQoL-8D contains
35 items which load onto eight dimensions. Three of
these dimensions are related to a physical ‘super-dimen-
sion’ and the remaining five to a psychosocial (‘mental’)
super-dimension [111]. The AQoL-8D has been found
to be valid and have good reliability compared to other
multi-attribute utility instruments and is particularly
suitable when evaluating economic outcomes where psy-
chosocial elements of health are of importance [112].
Adverse and serious adverse events
To assess the efficacy of the intervention, adverse events
will be recorded by the research team immediately upon
their notification. An adverse event will be defined as
‘any untoward medical occurrence in a participant sub-
ject to the intervention’. A severe adverse event will be
defined as ‘any event requiring hospitalisation or causing
an inability to carry out usual activities’. In the occur-
rence of any adverse or serious adverse event, the re-
search team will report to the governing ethics
committee, review relevant risk assessments, aim to
mitigate future risk of adverse events and provide the
appropriate duty of care to the participant/s concerned.
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Data collection, management and monitoring
The principle investigator and trained research assistants
will collect all data from the study participants. Inter-
and intra-tester reliability will be determined for data-
collecting investigators and research assistants for all
outcome measures as appropriate. Computer files con-
taining study data will be de-identified and password
protected with access only available to study investiga-
tors. Data entry will be performed in duplicate and ac-
curacy will be assessed with automatic cross-checking
procedures. Range checks for data values will be per-
formed to promote data quality. All hard-copy data files
will be stored in a securely locked filing cabinet at the
School of Human Movement and Nutrition Sciences,
The University of Queensland. Disposal of hard-copy
files will be performed in accordance with general proce-
dures, the regulations of the administering ethical board
and The University of Queensland.
Electronic copies of participant data and audio record-
ings and transcripts of peer supporter interviews will be
stored in various modes (computer hard drive; external
hard drive; and cloud-based systems) all of which will be
de-identified and password protected, maintaining confi-
dentiality at all times. Electronic data repositories will
only be accessible by the study investigators and associ-
ated data analysts. Results will be made available to par-
ticipants (including any publications that result from the
project) upon individual request following the comple-
tion of the study. Individual participants will not be
identified in any resultant manuscripts or reports of this
trial.
The investigators will comply with the Good Clinical
Practice (GCP) guidelines adopted by the Therapeutic
Goods Administration and will document and appropri-
ately address all adverse events through Human Re-
search Ethics Committee of Bellberry Ltd. The study
investigators will permit study-related monitoring, au-
dits, and inspections by Bellberry Ltd. of all study related
documents (e.g. source documents, regulatory docu-
ments, data collection instruments, study data) and
study facilities (e.g. diagnostic laboratory). An independ-
ent data monitoring committee is not needed, given the
role of Bellberry Ltd. This study will be conducted in full
conformance with the principles of the ‘Declaration of
Helsinki’ according to international standards of GCP
guidelines, applicable Australian government regula-
tions, and Institutional research policies and procedures.
Following study completion
On completion of a participant’s enrolment in the study,
they will be offered general exercise oncology recom-
mendations and directed to nearby community exercise
programs or Accredited Exercise Physiologists for con-
tinued care.
Statistical considerations and data analysis
A priori power calculations determined that a sample of
n = 188 (n = 94 per group) will be needed to detect a
minimum between-group difference in MVPA levels at
12 months, with 80% power and 5% alpha. To account
for an anticipated dropout rate of 20%, 226 participants
(n = 113 per group) will thus be recruited for this study.
A priori criteria for successful provision of peer support
will be contacting participants on average on one or
more occasions per week over the 12-month mainten-
ance phase.
Data will be assessed for normality of distribution
using the Kolmogorov-Smirnov test. Raw continuous
data (e.g. minutes of MVPA per day) will be analysed
using linear mixed (fixed and random) modeling, to as-
sess changes over time and differences between groups.
Group, time, and group × time interaction will be
treated as fixed factors; participants will be treated as a
random factor with individual intercepts. Each model
will include covariates, as appropriate, and will be ad-
justed using the baseline value as a fixed continuous co-
variate as previously described by Courneya et al. [113].
Model residuals will be formally assessed for normality
by use of the Kolmogorov-Smirnov test and visual in-
spection of histogram plots. Bonferroni pairwise adjust-
ments will be made for all subsequent comparisons.
Non-continuous data will be analysed with the target
distribution and relationship fixed to multinomial logis-
tic regression. Statistical significance will be set at an
alpha of p < .05 and analyses will be conducted using the
intention-to-treat approach. There are no interim ana-
lyses planned or early trial termination guidelines. Data
from the peer supporters will be analysed separately to
those of the participants.
Qualitative data from the semi-structured interview
transcripts will be assessed using inductive thematic ana-
lysis. Codes will be assigned to salient text segments
across the entire data set, before codes will be combined
to define overarching themes [108].
Economic evaluation
A cost-utility analysis (CUA) from a societal perspec-
tive will be undertaken using patient level data col-
lected alongside the clinical trial. A CUA compares
the incremental costs and benefits, expressed in
Quality Adjusted Life Years (QALYs) gained, of alter-
native programs. Costs will include direct costs (e.g.
intervention cost) as well as indirect costs (e.g. lost
productivity). Costs will be obtained by valuing the
resources consumed using unit prices from standard
costing resources such as the Medicare Benefits
Schedule and relevant award wages in Australia.
QALYs gained will be estimated, which is a measure
of a person’s life expectancy, weighted by their utility
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score measured using the Assessment of Quality of
Life – 8 dimensions (AQoL-8D) multi-attribute util-
ity instrument at baseline, immediately following the
supervised phase, and at 3, 6 and 12 months [111].
The incremental cost-effectiveness ratio (ICER) will
be calculated, which is the difference in mean costs
divided by the difference in mean QALYs. Sensitivity
analysis will be conducted to assess the impact of in-
put parameters (e.g. costs) on the results, and non-
parametric bootstrapping will be used to characterise
uncertainty around the ICER. In addition, sub-group
cost-effectiveness analysis will be performed to ex-
plore heterogeneity of results between patients’
subgroups.
Ethics and dissemination
This study has institutional ethical approval through the
Human Research Ethics Committee of Bellberry Ltd.
(#2015–12-840). Any future amendments to the protocol
and/or associated documents will be submitted for ap-
proval through Bellberry Ltd.
Outcomes of this trial will be published in inter-
national, high-quality, peer-reviewed journals, and the
findings will be presented at national and international
conferences and meetings. Findings will also be commu-
nicated at community and consumer-led forums and will
be presented at local hospital departments and university
seminars.
Discussion
The aim of the proposed trial is to determine the in-
fluence of peer support, compared to no peer sup-
port, on MVPA and various markers of health 12
months following a brief supervised exercise interven-
tion in cancer survivors. If peer support significantly
improves maintenance of MVPA compared to no peer
support, it will emerge as a potentially sustainable
and feasible means of enhancing cancer survivor’s en-
gagement in physical activity following completion of
a supervised exercise intervention. Further, should
peer support also be shown to enhance the mainten-
ance of physiological and psychosocial outcomes such
as cardiorespiratory fitness, body composition and
quality of life compared to no peer support, the long-
term health and wellbeing of people living with and
beyond cancer would be significantly improved. The
economic evaluation will also provide evidence of the
cost-effectiveness of peer support to maintain PA fol-
lowing a supervised exercise intervention.
Should peer support be shown to be (cost-) effect-
ive strategy to maintain MVPA following a super-
vised exercise intervention, it can potentially be
adopted and implemented at a national level through
existing peer support infrastructures of the State and
Territory Cancer Councils, the primary providers of
post-treatment support of cancer patients in
Australia. A peer support-exercise model has the
long-term potential to reduce comorbidities, improve
physical and mental wellbeing, and significantly re-
duce the burden of disease in cancer survivors.
Abbreviations
_VO2peak : Peak volume of oxygen consumption; AEP: Accredited Exercise
Physiologist; AQoL-8D: Assessment of Quality of Life – 8 dimensions multi-
attribute utility instrument; BMI: Body mass index; BSI: Brief Symptom
Inventory; CCQ: Cancer Council Queensland; CRP: C-reactive protein;
CUA: Cost utility analysis; DASS: Depression Anxiety Stress Scale; DXA: Dual
energy x-ray absorptiometry; ELISAs: Enzyme-linked immunosorbent assays;
EORTC QLQ-C30: European Organization for Research and Treatment of
Cancer quality of life questionnaire for people with cancer; FACIT-F: The
Functional Assessment of Chronic Illness Therapy: Fatigue; FACT-
G: Functional Assessment of Cancer Therapy: General; GAD-7: Generalised
Anxiety Disorder 7-item scale; GCP: Good Clinical Practice; HIIT: High intensity
interval training; HR: Heart rate; HRpeak: Peak heart rate; ICER: Incremental
cost-effectiveness ratio; IGF: Insulin-like growth factor; IGFBP: Insulin-like
growth factor binding protein; IL: Interleukin; ISAK: International Society for
the Advancement of Kinathropometry; ISI: Insomnia Severity Index;
MVPA: Moderate-to-vigorous physical activity; NHMRC: National Health and
Medical Research Council; PA: Physical activity; PHQ-9: Patient Health
Questionnaire-9; QALYs: Quality-adjusted life-years; RCT: Randomised
controlled trial; SF-36: Short form 36 health survey; TNF-α: Tumour necrosis




DGJ, TLS, SKC, JFA, JCD were responsible for the original conceptual design
of the study and with KSC, providing critical subsequent input. SRG provided
critical contribution regarding the physical activity components of the trial
and their subsequent analysis. KNA, KAB and CES have led development of
the biomarkers, the cancer-related fatigue and quality of life elements of the
project and are responsible for participant recruitment, testing, and data col-
lection. All authors read and approved the final manuscript.
Funding
This study is funded by the National Health and Medical Research Council
(NHMRC) (APP1132361) and Cancer Council Queensland (CCQ). NHMRC had
no role in the design of this study and will not have any role during its
execution, analyses, interpretation of the data, or decision to submit results.
Three authors are associated with CCQ, however no conflicts of interest are
declared and funding will have no bearing on any component of the study
conception, execution, analyses, interpretation or publication.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
This study has institutional ethical approval through the Human Research
Ethics Committee of Bellberry Ltd. (#2015–12-840). Written and informed
consent will be obtained from participating patients. Results of this RCT will
be reported in peer-reviewed publications, at national and international sci-





The authors declare that they have no competing interests.
Adlard et al. BMC Cancer          (2019) 19:656 Page 12 of 15
Author details
1School of Human Movement and Nutrition Sciences, The University of
Queensland, Brisbane, QLD, Australia. 2Department of Neurobiology, Care
Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 3School of
Health and Rehabilitation Sciences, The University of Queensland, Brisbane,
QLD, Australia. 4Cancer Council Queensland, Brisbane, QLD, Australia.
5Exercise Medicine Research Institute, Edith Cowan University, Perth, WA,
Australia. 6Institute for Resilient Regions, University of Southern QLD,
Springfield, QLD, Australia. 7Menzies Health Institute Queensland, Griffith
University, Nathan, QLD, Australia. 8School of Public Health, The University of
Queensland, Brisbane, QLD, Australia. 9Faculty of Health, University of
Technology Sydney, Sydney, NSW, Australia. 10School of Social Science, The
University of Queensland, Brisbane, QLD, Australia. 11Faculty of Kinesiology,
Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada.
Received: 8 May 2019 Accepted: 19 June 2019
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global
cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2018;68(6):394–424.
2. Courneya KS, Rogers LQ, Campbell KL, Vallance JK, Friedenreich CM. Top 10
research questions related to physical activity and cancer survivorship. Res
Q Exerc Sport. 2015;86(2):107–16.
3. Van Blarigan EL, Meyerhardt JA. Role of physical activity and diet after
colorectal cancer diagnosis. J Clin Oncol. 2015;33(16):1825–34.
4. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the
occurrence, assessment, and treatment of fatigue in cancer patients. J Natl
Cancer Inst Monogr. 2004;32:40–50.
5. Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE,
et al. Fatigue in long-term breast carcinoma survivors: a longitudinal
investigation. Cancer. 2006;106(4):751–8.
6. Schmid D, Leitzmann MF. Association between physical activity and
mortality among breast cancer and colorectal cancer survivors: a systematic
review and meta-analysis. Ann Oncol. 2014;25(7):1293–311.
7. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA,
et al. Physical activity and survival after colorectal cancer diagnosis. J Clin
Oncol. 2006;24(22):3527–34.
8. Irwin ML, Smith AW, McTiernan A, Ballard-Barbash R, Cronin K, Gilliland FD,
et al. Influence of pre- and postdiagnosis physical activity on mortality in
breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin
Oncol. 2008;26(24):3958–64.
9. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A,
Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer
survivors: a systematic review. J Natl Cancer Inst. 2012;104(11):815–40.
10. Meneses-Echavez JF, Gonzalez-Jimenez E, Ramirez-Velez R. Effects of
supervised multimodal exercise interventions on cancer-related fatigue:
systematic review and meta-analysis of randomized controlled trials.
Biomed Res Int. 2015;2015:3–15.
11. Mishra SI, Scherer RW, Snyder C, Geigle P, Gotay C. Are exercise programs
effective for improving health-related quality of life among cancer
survivors? A systematic review and meta-analysis. Oncol Nurs Forum. 2014;
41(6):326–42.
12. Cheema BS, Kilbreath SL, Fahey PP, Delaney GP, Atlantis E. Safety and
efficacy of progressive resistance training in breast cancer: a systematic
review and meta-analysis. Breast Cancer Res Treat. 2014;148(2):249–68.
13. Strasser B, Steindorf K, Wiskemann J, Ulrich CM. Impact of resistance
training in cancer survivors: a meta-analysis. Med Sci Sports Exerc.
2013;45(11):2080–90.
14. Kruijsen-Jaarsma M, Revesz D, Bierings MB, Buffart LM, Takken T. Effects of
exercise on immune function in patients with cancer: a systematic review.
Exerc Immunol Rev. 2013;19:120–43.
15. Schmitz KH, Holtzman J, Courneya KS, Masse LC, Duval S, Kane R. Controlled
physical activity trials in cancer survivors: a systematic review and meta-
analysis. Cancer Epidemiol Biomark Prev. 2005;14(7):1588–95.
16. Gibala MJ, McGee SL. Metabolic adaptations to short-term high-intensity
interval training: a little pain for a lot of gain? Exerc Sport Sci Rev. 2008;
36(2):58–63.
17. Whyte LJ, Gill JM, Cathcart AJ. Effect of 2 weeks of sprint interval training on
health-related outcomes in sedentary overweight/obese men. Metabolism.
2010;59(10):1421–8.
18. Wisloff U, Stoylen A, Loennechen JP, Bruvold M, Rognmo O, Haram PM, et
al. Superior cardiovascular effect of aerobic interval training versus
moderate continuous training in heart failure patients: a randomized study.
Circulation. 2007;115(24):3086–94.
19. Devin JL, Sax AT, Hughes GI, Jenkins DG, Aitken JF, Chambers SK, et al. The
influence of high-intensity compared with moderate-intensity exercise
training on cardiorespiratory fitness and body composition in colorectal
cancer survivors: a randomised controlled trial. J Cancer Surviv. 2016;10(3):
467–79.
20. Lakoski SG, Willis BL, Barlow CE, Leonard D, Gao A, Radford NB, et al. Midlife
cardiorespiratory fitness, incident cancer, and survival after cancer in men:
the Cooper Center longitudinal study. JAMA Oncol. 2015;1(2):231–7.
21. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA,
Pinto BM, et al. American College of Sports Medicine roundtable on
exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):
1409–26.
22. Cormie P, Atkinson M, Bucci L, Cust A, Eakin E, Hayes S, et al. Clinical
oncology Society of Australia position statement on exercise in cancer care.
Med J Aust. 2018;209(4):184–7.
23. Kampshoff CS, Chinapaw MJ, Brug J, Twisk JW, Schep G, Nijziel MR, et al.
Randomized controlled trial of the effects of high intensity and low-to-
moderate intensity exercise on physical fitness and fatigue in cancer
survivors: results of the resistance and endurance exercise after
ChemoTherapy (REACT) study. BMC Med. 2015;13:275–86.
24. Martin E, Battaglini C, Hands B, Naumann FL. Higher-intensity exercise helps
cancer survivors remain motivated. J Cancer Surviv. 2016;10(3):524–33.
25. Courneya KS, Katzmarzyk PT, Bacon E. Physical activity and obesity in
Canadian cancer survivors: population-based estimates from the 2005
Canadian community health survey. Cancer. 2008;112(11):2475–82.
26. Galvao DA, Newton RU, Gardiner RA, Girgis A, Lepore SJ, Stiller A, et al.
Compliance to exercise-oncology guidelines in prostate cancer survivors
and associations with psychological distress, unmet supportive care needs,
and quality of life. Psychooncology. 2015;24(10):1241–9.
27. Eakin EG, Youlden DR, Baade PD, Lawler SP, Reeves MM, Heyworth JS, et al.
Health behaviors of cancer survivors: data from an Australian population-
based survey. Cancer Causes Control. 2007;18(8):881–94.
28. Blanchard CM, Courneya KS, Stein K. Cancer survivors’ adherence to lifestyle
behavior recommendations and associations with health-related quality of
life: results from the American Cancer Society's SCS-II. J Clin Oncol. 2008;
26(13):2198–204.
29. Gomersall S, Maher C, English C, Rowlands A, Olds T. Time regained: when
people stop a physical activity program, how does their time use change?
A randomised controlled trial. PLoS One. 2015;10(5):18.
30. U.S. Department of Health and Human Services. Physical Activity Guidelines
for Americans. 2nd ed. Washington: U.S.: Department of Health and Human
Services; 2018.
31. Courneya K, Sellar C, Stevinson C, McNeely ML, Peddle CJ, Friedenreich CM,
et al. Randomized controlled trial of the effects of aerobic exercise on
physical functioning and quality of life in lymphoma patients. J Clin Oncol.
2009;27(27):4605–12.
32. Jankowski CM, Ory MG, Friedman DB, Dwyer A, Birken SA, Risendal B.
Searching for maintenance in exercise interventions for cancer survivors. J
Cancer Surviv. 2014;8(4):697–706.
33. Goode AD, Lawler SP, Brakenridge CL, Reeves MM, Eakin EG. Telephone,
print, and web-based interventions for physical activity, diet, and weight
control among cancer survivors: a systematic review. J Cancer Surviv. 2015;
9(4):660–82.
34. Finlay A, Wittert G, Short CE. A systematic review of physical activity-based
behaviour change interventions reaching men with prostate cancer. J
Cancer Surviv. 2018;12(4):571–91.
35. Fjeldsoe B, Neuhaus M, Winkler E, Eakin E. Systematic review of
maintenance of behavior change following physical activity and dietary
interventions. Health Psychol. 2011;30(1):99–109.
36. Bandura A. Social foundations of thought and action: A social cognitive
theory. Pearson Education: Englewood Cliffs, NJ; 1986. 640 p.
37. Ajzen I. The theory of planned behaviour is alive and well, and not ready to
retire: a commentary on Sniehotta, Presseau, and Araujo-Soares. Health
Psychol Rev. 2015;9(2):131–7.
Adlard et al. BMC Cancer          (2019) 19:656 Page 13 of 15
38. Clark AM, Munday C, McLaughlin D, Catto S, McLaren A, Macintyre PD. Peer
support to promote physical activity after completion of Centre-based
cardiac rehabilitation: evaluation of access and effects. Eur J Cardiovasc
Nurs. 2012;11(4):388–95.
39. Ginis KA, Nigg CR, Smith AL. Peer-delivered physical activity interventions:
an overlooked opportunity for physical activity promotion. Transl Behav
Med. 2013;3(4):434–43.
40. Pinto BM, Stein K, Dunsiger S. Peers promoting physical activity among
breast cancer survivors: a randomized controlled trial. Health Psychol. 2015;
34(5):463–72.
41. Pinto B, Stein K, Dunsiger S. Peer mentorship to promote physical activity
among cancer survivors: effects on quality of life. Psychooncology. 2015;
24(10):1295–302.
42. Faulkner G, Gorczynski P, Arbour K, Letts L, Wolfe D, Ginis KA. Messengers
and methods of disseminating health information among individuals with
spinal cord injury: a scoping review. In: Handbook of Spinal Cord Injuries:
Types, Treatments and Prognosis. Hauppauge: Nova Science Publishers;
2009. p. 349–74.
43. American College of Sports Medicine. ACSM’s Guidelines for Exercise
Testing and Prescription. 10th ed. Philadelphia: Lippincot Williams and
Wilkins; 2018.
44. Troiano RP, Berrigan D, Dodd KW, Masse LC, Tilert T, McDowell M. Physical
activity in the United States measured by accelerometer. Med Sci Sports
Exerc. 2008;40(1):181–8.
45. Matthews CE, Chen KY, Freedson PS, Buchowski MS, Beech BM, Pate RR, et
al. Amount of time spent in sedentary behaviors in the United States, 2003-
2004. Am J Epidemiol. 2008;167(7):875–81.
46. Schmid D, Leitzmann MF. Cardiorespiratory fitness as predictor of
cancer mortality: a systematic review and meta-analysis. Ann Oncol.
2015;26(2):272–8.
47. Pozuelo-Carrascosa DP, Alvarez-Bueno C, Cavero-Redondo I, Morais S, Lee
IM, Martinez-Vizcaino V. Cardiorespiratory fitness and site-specific risk of
cancer in men: A systematic review and meta-analysis. Eur J Cancer. 2019;
113:58–68.
48. Devin JL, Jenkins DG, Sax AT, Hughes GI, Aitken JF, Chambers SK, et al.
Cardiorespiratory fitness and body composition responses to different
intensities and frequencies of exercise training in colorectal cancer survivors.
Clin Colorectal Cancer. 2018;17(2):269–79.
49. Clark W, Siegel EM, Chen YA, Zhao X, Parsons CM, Hernandez JM, et al.
Quantitative measures of visceral adiposity and body mass index in
predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am
Coll Surg. 2013;216(6):1070–81.
50. Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT. The role of
body composition evaluation by computerized tomography in determining
colorectal cancer treatment outcomes: a systematic review. Eur J Surg
Oncol. 2015;41(2):186–96.
51. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, Lim-Joon D, Bolton D, Zebaze R,
et al. Structural decay of bone microarchitecture in men with prostate
cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab.
2010;95(12):456–63.
52. Bolam KA, Skinner TL, Jenkins DG, Galvao DA, Taaffe DR. The osteogenic
effect of impact-loading and resistance exercise on bone mineral density in
middle-aged and older men: a pilot study. Gerontology. 2015;62(1):22–32.
53. Vissers PA, Martucci RB, Mols F, Bours MJ, Winkels RM, Kampman E, et al.
The impact of body mass index and waist circumference on health-related
quality of life among colorectal cancer survivors: results from the PROFILES
registry. Nutr Cancer. 2017;69(8):1177–84.
54. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet
Oncol. 2002;3(9):565–74.
55. Dong Y, Zhou J, Zhu Y, Luo L, He T, Hu H, et al. Abdominal obesity and
colorectal cancer risk: systematic review and meta-analysis of prospective
studies. Biosci Rep. 2017;37(6):12.
56. Bardou M, Barkun AF, Martel M. Obesity and colorectal cancer. Gut. 2013;
62(6):933–47.
57. Stewart A, Marfell-Jones M, Olds T. International standards of
anthropometric assessment. International Society for the Advancement of
Kinanthropometry: New Zealand; 2011.
58. Swellengrebel HA, Marijnen CA, Verwaal VJ, Vincent A, Heuff G,
Gerhards MF, et al. Toxicity and complications of preoperative
chemoradiotherapy for locally advanced rectal cancer. Br J Surg. 2011;
98(3):418–26.
59. Padilha CS, Marinello PC, Galvao DA, Newton RU, Borges FH, Frajacomo F, et
al. Evaluation of resistance training to improve muscular strength and body
composition in cancer patients undergoing neoadjuvant and adjuvant
therapy: a meta-analysis. J Cancer Surviv. 2017;11(3):339–49.
60. Stevens PJ, Syddall HE, Patel HP, Martin HJ, Cooper C, Aihie SA. Is grip
strength a good marker of physical performance among community-
dwelling older people? J Nutr Health Aging. 2012;16(9):769–74.
61. Coombes JS, Skinner TL. ESSA’s student manual for health, Exercise and
Sport Assessment. Chatswood: Elsevier Health Sciences; 2014.
62. Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, et al. Inflammatory
biomarkers and fatigue during radiation therapy for breast and prostate
cancer. Clin Cancer Res. 2009;15(17):5534–40.
63. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory
biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res.
2006;12(9):2759–66.
64. Sax AT, Jenkins DG, Devin JL, Hughes GI, Bolam KA, Skinner TL. The
insulin-like growth factor axis: A biological mechanism linking
physical activity to colorectal cancer survival. Cancer Epidemiol. 2014;
38(4):455–9.
65. Aziz N, Nishanian P, Mitsuyasu R, Detels R, Fahey J. Variables that affect
assays for plasma cytokines and soluble activation markers. Clin Diagn Lab
Immunol. 1999;6(1):89–95.
66. Troiano RP, Pettee Gabriel KK, Welk GJ, Owen N, Sternfeld B. Reported
physical activity and sedentary behavior: why do you ask? J Phys Act Health.
2012;9(1):68–75.
67. Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et
al. Exercise interventions on health-related quality of life for cancer
survivors. Cochrane Database Syst Rev. 2012;8(8):380.
68. Church TS, Thomas DM, Tudor-Locke C, Katzmarzyk PT, Earnest CP, Rodarte
RQ, et al. Trends over 5 decades in US occupation-related physical activity
and their associations with obesity. PLoS One. 2011;6(5):11.
69. Godin G, Shephard RJ. A simple method to assess exercise behavior in the
community. Can J Appl Sport Sci. 1985;10(3):141–6.
70. Amireault S, Godin G. The Godin-Shephard leisure-time physical activity
questionnaire: validity evidence supporting its use for classifying healthy
adults into active and insufficiently active categories. Percept Mot Skills.
2015;120(2):604–22.
71. Amireault S, Godin G, Lacombe J, Sabiston CM. The use of the Godin-
Shephard leisure-time physical activity questionnaire in oncology
research: a systematic review. BMC Med Res Methodol. 2015;15:60–70.
72. Amireault S, Godin G, Lacombe J, Sabiston C. Validation of the Godin-
Shephard leisure-time physical activity questionnaire classification coding
system using accelerometer assessment among breast cancer survivors. J
Cancer Surviv. 2015;9(3):532–40.
73. Lynch BM, Dunstan DW, Vallance JK, Owen N. Don't take cancer sitting
down: a new survivorship research agenda. Cancer. 2013;119(11):1928–35.
74. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera
EV, et al. American Cancer Society guidelines on nutrition and physical
activity for cancer prevention: reducing the risk of cancer with healthy food
choices and physical activity. CA Cancer J Clin. 2012;62(1):30–67.
75. Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour,
diet, and cancer: an update and emerging new evidence. Lancet Oncol.
2017;18(8):457–71.
76. van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, et al.
An international field study of the EORTC QLQ-PR25: a questionnaire for
assessing the health-related quality of life of patients with prostate
cancer. Eur J Cancer. 2008;44(16):2418–24.
77. Chiu L, Chiu N, Chow E, Cella D, Beaumont J, Lam H, et al. Comparison of
three shortened questionnaires for assessment of quality of life in advanced
cancer. J Palliat Med. 2014;17(8):918–23.
78. Ganesh V, Agarwal A, Popovic M, Cella D, McDonald R, Vuong S, et al.
Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life
questionnaires for patients with colorectal cancer: a literature review.
Support Care Cancer. 2016;24(8):3661–8.
79. Chu D, Popovic M, Chow E, Cella D, Beaumont JL, Lam H, et al.
Development, characteristics and validity of the EORTC QLQ-PR25 and the
FACT-P for assessment of quality of life in prostate cancer patients. J Comp
Eff Res. 2014;3(5):523–31.
80. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey
(SF-36). I. Conceptual framework and item selection. Med Care. 1992;
30(6):473–83.
Adlard et al. BMC Cancer          (2019) 19:656 Page 14 of 15
81. Ware JE, Gandek B. Overview of the SF-36 health survey and the
international quality of life assessment (IQOLA) project. J Clin Epidemiol.
1998;51(11):903–12.
82. Cella D, Tulsky D, Gray G, Sarafian B, Linn E, Bonomi A, et al. The
functional assessment of Cancer therapy scale: development and
validation of the general measure. J Clin Oncol. 1993;11(3):570–9.
83. Cella D. The functional assessment of Cancer therapy-lung and lung
Cancer subscale assess quality of life and meaningful symptom
improvement in lung cancer. Semin Oncol. 2004;31(3):11–5.
84. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and
other anemia-related symptoms with the functional assessment of Cancer
therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63–74.
85. Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE. Combining anchor and
distribution-based methods to derive minimal clinically important
differences on the functional assessment of Cancer therapy (FACT) Anemia
and fatigue scales. J Pain Symptom Manag. 2002;24(6):547–61.
86. Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the
functional assessment of chronic illness therapy measurement system. Arch
Phys Med Rehabil. 2002;83(12):10–7.
87. Bastien CH, Vallieres A, Morin CM. Validation of the insomnia severity index
as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–
307.
88. Morin CM, Belleville G, Belanger L, Ivers H. The insomnia severity index:
psychometric indicators to detect insomnia cases and evaluate treatment
response. Sleep. 2011;34(5):601–8.
89. Savard MH, Savard J, Simard S, Ivers H. Empirical validation of the insomnia
severity index in cancer patients. Psychooncology. 2005;14(6):429–41.
90. Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory
report. Psychol Med. 1983;13(3):595–605.
91. Derogatis LR. BSI-18, brief symptom inventory 18: administration, Scoring
and Procedures Manual. Minneappolis: NCS Pearson, Incorporated; 2001.
92. Chambers SK, Girgis A, Occhipinti S, Hutchison S, Turner J, Carter R, et al.
Beating the blues after cancer: randomised controlled trial of a tele-based
psychological intervention for high distress patients and carers. BMC Cancer.
2009;9:189–95.
93. Lovibond S, Lovibond P. Manual for the Depression Anxiety Stress Scales.
Sydney: Psychology Foundation of Australia; 1995.
94. Ng F, Trauer T, Dodd S, Callaly T, Campbell S, Berk M. The validity of the 21-
item version of the depression anxiety stress scales as a routine clinical
outcome measure. Acta Neuropsychiatr. 2007;19(5):304–10.
95. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer
Inst Monogr. 2004;2004(32):57–71.
96. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression
severity measure. J Gen Intern Med. 2001;16(9):606–13.
97. Kroenke K, Spitzer RL, Williams JB, Lowe B. The patient health questionnaire
somatic, anxiety, and depressive symptom scales: a systematic review. Gen
Hosp Psychiatry. 2010;32(4):345–59.
98. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders
in primary care: prevalence, impairment, comorbidity, and detection. Ann
Intern Med. 2007;146(5):317–25.
99. Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety
in long-term cancer survivors compared with spouses and healthy controls:
a systematic review and meta-analysis. Lancet Oncol. 2013;14(8):721–32.
100. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing
generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):
1092–7.
101. Bordin ES. The generalizability of the psychoanalytic concept of the working
alliance. Psychotherapy (Chic). 1979;16(3):252–60.
102. Hatcher RL, A. G. Development and validation of a revised short version of
the working Alliance inventory. Psychother Res. 2006;16(1):12–25.
103. Horvath AO, Greenberg LS. Development and validation of the working
Alliance inventory. J Couns Psychol. 1989;36(2):223–33.
104. Resnick B, Jenkins L. Testing the reliability and validity of the self-efficacy for
exercise scale. Nurs Res. 2000;49(3):154–9.
105. Evenson KR, Aytur SA, Borodulin K. Physical activity beliefs, barriers, and
enablers among postpartum women. J Women's Health (Larchmt). 2009;
18(12):1925–34.
106. Macniven R, Pye V, Merom D, Milat A, Monger C, Bauman A, et al. Barriers
and enablers to physical activity among older Australians who want to
increase their physical activity levels. J Phys Act Health. 2014;11(7):1420–9.
107. Markland D, Tobin V. A modification to the behavioural regulation in
exercise questionnaire to include an assessment of amotivation. J Sport
Exerc Psychol. 2004;26(2):191–6.
108. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3(2):77–101.
109. Baumann F, Bieck O, Oberste M, Kuhn R, Schmitt J, Wentrock S, et al.
Sustainable impact of an individualized exercise program on physical
activity level and fatigue syndrome on breast cancer patients in two
German rehabilitation centers. Support Care Cancer. 2017;25(4):1047–54.
110. Burton N, Khan A, Brown W. How, where and with whom? Physical activity
context preferences of three adult groups at risk of inactivity. Br J Sports
Med. 2012;46(16):1125–31.
111. Richardson J, Atherton Day N, Peacock S, Iezzi A. Measurement of the
quality of life for economic evaluation and the assessment of quality of life
(AQoL) mark 2 instrument. Aust Econ Rev. 2004;37(1):62–88.
112. Richardson J, Iezzi A, Khan MA, Maxwell A. Validity and reliability of the
assessment of quality of life (AQoL)-8D multi-attribute utility instrument.
Patient. 2014;7(1):85–96.
113. Courneya K, Segal R, Mackey J, Gelmon K, Reid R, Friedenreich C, et al.
Effects of aerobic and resistance exercise in breast cancer patients receiving
adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin
Oncol. 2007;25(28):4396–404.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Adlard et al. BMC Cancer          (2019) 19:656 Page 15 of 15
